Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)
$11.0400
-0.7500 ( -5.48% ) 942.9K
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
Market Data
Open
$11.0400
Previous close
$11.7900
Volume
942.9K
Market cap
$1.20B
Day range
$10.8930 - $12.1180
52 week range
$10.8930 - $31.4700
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | May 20, 2024 |
| 4 | Insider transactions | 1 | May 20, 2024 |
| 10-q | Quarterly Reports | 88 | May 07, 2024 |
| 8-k | 8K-related | 15 | May 06, 2024 |
| def | Proxies and info statements | 20 | Apr 29, 2024 |
| ars | Annual reports | 1 | Apr 29, 2024 |
| 4 | Insider transactions | 1 | Apr 24, 2024 |
| pre | Proxies and info statements | 20 | Apr 17, 2024 |
| 4 | Insider transactions | 1 | Apr 16, 2024 |
| 4 | Insider transactions | 1 | Apr 10, 2024 |